| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-08-25 | recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) | hemophilia A with inhibitors, hemophilia B with inhibitors | 2-3 | CSL (Australia) | Rare diseases - Genetic diseases - Hematological diseases |
| 2015-08-24 | liver cancer | Integragen (France) Inserm (France) AP-HP (France) | Cancer - Oncology | ||
| 2015-08-24 | BioChaperone Lispro (new and more concentrated formulation) | type 1 diabetes mellitus | 1 | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-08-24 | Yeliva™(ABC294640) | prostate cancer | preclinical | Redhill Biopharma (Israel) | Cancer - Oncology |
| 2015-08-23 | BMS-986165 | lupus, psoriasis | 1 | BMS (USA - NY) | Autoimmune diseases - Dermatological diseases |
| 2015-08-22 | aceneuramic acid extended release (Ace-ER), previously known as sialic acid-extended release (SA-ER; UX001) | GNE myopathy, also known as hereditary inclusion body myopathy (HIBM) | 3 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2015-08-21 | DCVax®-L | glioblastoma multiforme | 3 | Northwest Biotherapeutics (USA - MD) | Cancer - Oncology |
| 2015-08-21 | apalutamide (ARN-509, JNJ-56021927) | prostate cancer | 3 | Aragon Pharmaceuticals (USA - CA), now Johnson&Johnson (J&J) (USA - NJ) | Cancer - Oncology |
| 2015-08-20 | Lymphoseek® (technetium Tc 99m tilmanocept) | breast cancer | Navidea Biopharmaceuticals (USA - OH) | Cancer - Oncology | |
| 2015-08-20 | V158866 (fatty acid amide hydrolase (FAAH) inhibitor) | neuropathic pain as a result of spinal cord injury | 2a | Vernalis (UK) | CNS diseases - Neurological diseases |
| 2015-08-20 | SAR366234 | open angle glaucoma - ocular hypertension | 1 | Sanofi (France) | Ophtalmological diseases |
| 2015-08-18 | MVA-BN® RSV vaccine | respiratory syncytial virus infections | 1 | Bavarian Nordic (Denmark) | Infectious diseases - Respiratory diseases |
| 2015-08-18 | liquid biopsy test for bladder cancer | bladder cancer | MDxHealth (Belgium) University Erasmus Medical Center (Belgium) | Cancer - Oncology - Diagnostic | |
| 2015-08-17 | SMT C1100 | Duchenne muscular dystrophy (DMD) | 1b | Summit Therapeutics (UK) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2015-08-17 | RT001 | Friedreich\'s ataxia | 1-2 | Retrotope (USA - CA) | Rare diseases - Genetic diseases - Neurodegenerative diseases |
| 2015-08-17 | MPDL3280A (atezolizumab) | people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1) |
2 | Roche (Switzerland) | Cancer - Oncology |
| 2015-08-17 | SAGE-547 | super-refractory status epilepticus (SRSE) | 3 | Sage Therapeutics (USA - MA) | CNS diseases - Neurological diseases |
| 2015-08-17 | BL-8040 | consolidation treatment for acute myeloid leukemia (AML) patients who have responded to standard induction treatment | 2b | BioLineRx (Israel) | Cancer - Oncology |
| 2015-08-14 | JR-051 (recombinant alpha-galactosidase A) | Fabry disease | JCR Pharmaceuticals (Japan) GSK (UK) | Rare diseases - Genetic diseases | |
| 2015-08-13 | CAT-2054 | 1 | Catabasis Pharmaceuticals (USA - MA) | Metabolic diseases |
